FDA decision to restrict ESAs may boost business for Cerus

09/15/2008 | East Bay (Calif.) Business Times

The FDA's decision to restrict the use of erythropoiesis-stimulating agents in cancer patients with anemia likely will boost the number of blood transfusions in the U.S., said Dr. Laurence Corash, chief medical officer of Cerus Corp. The change is expected to increase demand for the company's products, including the Intercept blood-safety system, which has yet to obtain FDA approval.

View Full Article in:

East Bay (Calif.) Business Times

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI